Use of Real-World EMR Data to Rapidly Evaluate Treatment Effects of Existing Drugs for Emerging Infectious Diseases: Remdesivir for COVID-19 Treatment as an Example

Chenguang Zhang, Masayuki Nigo, Shivani Patel, Duo Yu, Edward Septimus and Hulin Wu ()
Additional contact information
Chenguang Zhang: University of Texas Health Science Center at Houston
Masayuki Nigo: University of Texas Health Science Center at Houston
Shivani Patel: Memorial Hermann Health System
Duo Yu: Medical College of Wisconsin
Edward Septimus: Memorial Hermann Health System
Hulin Wu: University of Texas Health Science Center at Houston

Statistics in Biosciences, 2024, vol. 16, issue 3, No 5, 604-633

Abstract: Abstract For an emerging infectious disease such as 2019 coronavirus disease (COVID-19), initially there may not be any existing medication or treatment immediately available, which may result in high morbidity and mortality in a short time of period. In this case, it is urgent to quickly identify whether existing medications or treatments could be repurposed to treat the newly appeared disease before time-consuming randomized clinical trials (RCTs) can be done and new drugs can be developed. For example, when SARS-CoV-2 appeared in late 2019, clinicians started to use existing antiviral drugs, anti-inflammatory drugs, immune-based therapies and other types of medications to treat COVID-19 patients before any data or evidence was available to support the use of these medications for the new COVID-19 disease. Most of these medications have proven to be ineffective or only marginally effective to treat COVID-19 patients by more rigorous RCT or secondary data analyses later. We propose to use real-world electronic medical records (EMR) data to develop real-time treatment evaluation and monitoring systems to identify effective treatments or avoid ineffective treatments for emerging diseases in the future. In order to do this, first we have to deal with the challenges in processing and analyzing complex and noisy EMR data. In this paper, we outline these challenges and propose practical statistical methods and guidelines, which are derived from a project in evaluating anti-viral medication, remdesivir, for COVID-19 treatment based on a local healthcare EMR database.

Keywords: Causal inference; Competing risks; EMR; Propensity score; SARS-CoV-2; Real-world data (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s12561-023-09411-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:stabio:v:16:y:2024:i:3:d:10.1007_s12561-023-09411-8

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/12561

DOI: 10.1007/s12561-023-09411-8

Access Statistics for this article

Statistics in Biosciences is currently edited by Hongyu Zhao and Xihong Lin

More articles in Statistics in Biosciences from Springer, International Chinese Statistical Association
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().